4-溴-2-异丙氧基-1-甲氧基苯 | 462092-23-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 4-溴-2-异丙氧基-1-甲氧基苯
• 英文名称: 4-bromo-2-isopropoxy-1-methoxybenzene
• 英文别名: 4-bromo-2-isopropoxy-1-methoxy-benzene；4-bromo-1-methoxy-2-propan-2-yloxybenzene
• CAS: 462092-23-5
• 化学式: C₁₀H₁₃BrO₂
• 分子量: 245.116
• InChiKey: MOYPCCQJVWYSQF-UHFFFAOYSA-N

物化性质

• 熔点：
  46-46.5 °C
• 沸点：
  263.7±20.0 °C(Predicted)
• 密度：
  1.310±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2909309090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Bromo-2-isopropoxy-1-methoxybenzene
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Bromo-2-isopropoxy-1-methoxybenzene
CAS number: 462092-23-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H13BrO2
Molecular weight: 245.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-溴-2-异丙氧基-1-甲氧基苯 在 palladium diacetate 、 四(三苯基膦)钯 氢氧化钾 、 三氟化硼乙醚 、 叔丁基锂 、 三氯化硼 、 sodium carbonate 、 2,3-二氯-5,6-二氰基-1,4-苯醌 、 [双(三氟乙酰氧基)碘]苯 作用下， 以 四氢呋喃 、 乙醇 、 正庚烷 、 二氯甲烷 、 水 、 甲苯 、 乙腈 、 正戊烷 为溶剂， 反应 59.5h， 生成 3,11-dihydroxy-14-(3-hydroxy-4-methoxyphenyl)-2,12-dimethoxy-6H-[1]benzopyrano-[4′,3′:4,5]pyrrolo[2,1-a]isoquinolin-6-one
  参考文献：
  名称：

  薄片蛋白D，L和N的全合成

  摘要：

  通过使用Hinsberg型吡咯合成法和钯催化的3,4-二羟基吡咯二酚6的Suzuki-Miyaura偶联，已经完成了细胞毒性海洋生物碱，薄片蛋白D，L和N的总合成。普通中间体6的层状蛋白D，L和N的总产率分别为54％，58％和50％。

  DOI：

  10.1016/j.tet.2005.10.014
• 作为产物：
  描述：

  2,4-二溴苯甲醚 在 正丁基锂 、 potassium carbonate 作用下， 以 乙醚 、 正己烷 、 二甲基亚砜 为溶剂， 反应 19.0h， 生成 4-溴-2-异丙氧基-1-甲氧基苯
  参考文献：
  名称：

  薄片蛋白D，L和N的全合成

  摘要：

  通过使用Hinsberg型吡咯合成法和钯催化的3,4-二羟基吡咯二酚6的Suzuki-Miyaura偶联，已经完成了细胞毒性海洋生物碱，薄片蛋白D，L和N的总合成。普通中间体6的层状蛋白D，L和N的总产率分别为54％，58％和50％。

  DOI：

  10.1016/j.tet.2005.10.014

文献信息

• An acyl-Claisen/Paal-Knorr approach to fully substituted pyrroles
  作者：Nora Dittrich、Eun-Kyung Jung、Samuel J. Davidson、David Barker

  DOI：10.1016/j.tet.2016.06.049

  日期：2016.8

  The synthesis of fully substituted pyrroles using the Paal-Knorr reaction on acyl-Claisen derived 2,3-syn-disubstituted-1,4-diketones is reported. The use of the acyl-Claisen rearrangement allows the synthesis of wide variety of syn-substituted 1,4-diketones which are shown to be better substrates for pyrrole condensation than their corresponding anti isomers. When the reaction was performed open to

  报道了在酰基-克莱森衍生的2，3-顺-二取代-1，4-二酮上使用Paal-Knorr反应合成完全取代的吡咯。使用酰基Claisen重排的允许的各种合成顺式-取代的1,4-二酮类，其被示出为用于吡咯缩合比其相应的底物更好的抗异构体。当反应在空气中进行时，在吡咯形成步骤中使用亲核胺会导致5-甲基自动氧化，仅生成5-甲酰基吡咯。
• Combretastatin analogs with tubulin binding activity
  申请人：Pinney G. Kevin

  公开号：US20060293394A1

  公开（公告）日：2006-12-28

  Analogs of combretastatin have been discovered which demonstrate impressive cytotoxicity as well as a remarkable ability to inhibit tubulin polymerization. Such compounds are excellent clinical candidates for the treatment of cancer in humans. In addition, certain of these ligands, as pro-drugs, may well prove to be tumor selective vascular targeting chemotherapeutic agents or to have vascular targeting activity resulting in the selective prevention and/or destruction of nonmalignant proliferating vasculature.

  已经发现了与康柏他斯汀类似的化合物，它们展示出令人印象深刻的细胞毒性，以及抑制微管聚合的显著能力。这些化合物是治疗人类癌症的优秀临床候选药物。此外，这些配体中的某些作为前药，很可能证明是肿瘤选择性血管靶向化疗药物，或具有血管靶向活性，导致选择性预防和/或破坏非恶性增殖的血管。
• Boron Containing PDE4 Inhibitors
  申请人：Pfizer Inc.

  公开号：US20200108083A1

  公开（公告）日：2020-04-09

  The present invention relates to boron containing compounds of Formula (I) X—Y—Z   Formula (I) that inhibit phosphodiesterase 4 (PDE4). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating diseases, conditions, or disorders ameliorated by inhibition of PDE4.

  本发明涉及具有化学式（I）X—Y—Z的含硼化合物，化学式（I）抑制磷酸二酯酶4（PDE4）。该发明还涵盖含有这些化合物的药物组合物以及通过抑制PDE4治疗疾病、症状或障碍的方法。
• Synthesis and biological activity of pyrrole analogues of combretastatin A-4
  作者：Eun-Kyung Jung、Euphemia Leung、David Barker

  DOI：10.1016/j.bmcl.2016.05.026

  日期：2016.7

  A series of pyrrole analogues of combretastatin (CA-4) were synthesized and tested for their anti-proliferative activity. The highly diastereoselective acyl-Claisen rearrangement was used to provide 2,3-syn disubstituted morpholine amides which were used as precursors for the various analogues. This synthesis allows for the preparation of 1,2- and 2,3-diaryl-1H-pyrroles which are both geometrically

  合成了康普他汀的一系列吡咯类似物（CA-4），并测试了它们的抗增殖活性。高度非对映选择性的酰基-克莱森重排用于提供2，3-顺式双取代的吗啉酰胺，其用作各种类似物的前体。该合成允许制备在几何上均类似于CA-4的1,2-和2,3-二芳基-1 H-吡咯。测试了这些吡咯类似物对两种人类细胞系K562和MDA-MB-231的抗增殖活性，其中2,3-二芳基-1 H-吡咯35表现出最强的活性，针对MDA的IC 50值为0.07μM -MB-231细胞系。
• Pyrrolopyridazinone Compound
  申请人：Hagihara Masahiko

  公开号：US20090036453A1

  公开（公告）日：2009-02-05

  The present invention discloses a pyrrolopyridazinone compound represented by the formula (1): wherein R 1 represents C 1 -C 2 alkyl group or halogeno C 1 -C 2 alkyl group, R 2 repersents C 3 -C 5 cycloalkyl group, (C 3 -C 5 cycloalkyl)C 1 -C 2 alkyl group or C 1 -C 3 alkyl group, R 3 represents hydrogen atom, or methylene group or cis-vinylene group for forming substituted oxygen-containing hetero ring in combination with group —O—R 2 , R 4 represents hydrogen atom, halogen atom, C 1 -C 8 alkyl group, C 2 -C 6 alkenyl group, C 2 -C 6 alkynyl group, hydroxy C 3 -C 6 alkenyl group, hydroxy C 3 -C 6 alkynyl group, C 1 -C 6 alkyl group substituted by substituent(s) selected from Substituent group (a), C 3 -C 6 cycloalkyl group which may be substituted by substituent(s) selected from Substituent group (b), “C 1 -C 3 alkyl group which is substituted by C 3 -C 6 cycloalkyl group which may be substituted by substituent(s) selected from Substituent group (b), and which may be substituted by a hydroxy group”, an aromatic ring group or heteroaromatic ring group each of which may be substituted by a substituent(s) selected from Substituent group (c) or “C 1 -C 2 alkyl group which is substituted by aromatic ring group or heteroaromatic ring group each of which may be substituted by group(s) selected from Substituent group (c), and which may be substituted by a hydroxy group”, Substituent group (a) represents a halogen atom, hydroxy group, cyano group, carboxy group, C 1 -C 5 alkoxy group, halogeno C 1 -C 4 alkoxy group, C 3 -C 6 cycloalkoxy group, (C 3 -C 6 cycloalkyl)C 1 -C 2 alkoxy group, C 1 -C 4 alkoxycarbonyl group, C 2 -C 4 alkanoyl group, C 2 -C 4 alkanoyloxy group or C 1 -C 4 alkyl-substituted amino group, Substituent group (b) represents a hydroxy group or a halogen atom, Substituent group (c) represents a halogen atom, a hydroxy group, a cyano group, a nitro group, a carboxy group, C 1 -C 5 alkoxy group, C 1 -C 4 alkoxycarbonyl group, C 2 -C 4 alkanoyloxy group, C 1 -C 4 alkyl-substituted amino group or a C 1 -C 4 alkyl group which may be substituted by a substituent(s) selected from the group consisting of (a halogen atom, a hydroxy group and a carboxy group), or a pharmaceutically acceptable salt thereof.

  本发明公开了一种由式（1）表示的吡咯吡啶二酮化合物：其中，R1代表C1-C2烷基或卤代C1-C2烷基，R2代表C3-C5环烷基、（C3-C5环烷基）C1-C2烷基或C1-C3烷基，R3代表氢原子，或与基团-O-R2结合形成取代含氧杂环的亚甲基或顺式乙烯基，R4代表氢原子、卤素原子、C1-C8烷基、C2-C6烯基、C2-C6炔基、羟基C3-C6烯基、羟基C3-C6炔基、由从取代基团（a）中选择的取代基团取代的C1-C6烷基，可由从取代基团（b）中选择的取代基团取代的C3-C6环烷基，可由从取代基团（b）中选择的取代基团取代的C1-C3烷基，且可由羟基取代，芳香环基或杂芳香环基，每个都可由从取代基团（c）中选择的取代基团取代或由取代基团（c）选择的基团取代的C1-C2烷基，且可由羟基取代，取代基团（a）表示卤素原子、羟基、氰基、羧基、C1-C5烷氧基、卤代C1-C4烷氧基、C3-C6环烷氧基、（C3-C6环烷基）C1-C2烷氧基、C1-C4烷氧羰基、C2-C4酰基、C2-C4酰氧基或C1-C4烷基取代的氨基基团，取代基团（b）表示羟基或卤素原子，取代基团（c）表示卤素原子、羟基、氰基、硝基、羧基、C1-C5烷氧基、C1-C4烷氧羰基、C2-C4酰氧基、C1-C4烷基取代的氨基基团或可由从由卤素原子、羟基和羧基组成的基团中选择的取代基团取代的C1-C4烷基，或其药学上可接受的盐。